ALX Oncology Announces Closing of $105 Million Series C Financing
Proceeds to Advance and Expand ALX148 Clinical Program DUBLIN, Ireland and BURLINGAME, Calif. – February 12, 2020 – ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing. Vivo Capital was the lead investor with other new investors including funds managed […]
